Latest News
May 21, 2013
Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.
April 23, 2013
Intercell Annual Report 2012
March 20, 2013
Updated Financial Calender 2013
March 05, 2013
Intercell AG announces Q4 and preliminary full year 2012 financial results and business update
February 28, 2013
Webcast link for Q4 2012 results
February 27, 2013
Intercell AG - Extraordinary General Meeting approved proposed merger of equals with Vivalis SA to create Valneva SE
February 12, 2013
Intercell announces pediatric approval of its Japanese Encephalitis vaccine in Europe
December 19, 2012
Intercell receives CHMP positive opinion for the pediatric indication of its Japanese Encephalitis vaccine in Europe
December 16, 2012
Proposed Merger of Equals between Vivalis and Intercell - Creation of a European Biotech Leader in Vaccines and Antibodies
October 30, 2012
Webcast link for Q3 2012 results
October 16, 2012
Intercell provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance
September 18, 2012
Intercell announces Phase I results on its Vaccine Enhancement Patch (VEP) with Pandemic Influenza antigens
September 13, 2012
Intercell’s partner Biological E. Ltd. launches Japanese Encephalitis vaccine JEEV® in India
August 07, 2012
Intercell AG announces Q2 and H1 2012 financial results and provides operational update
July 31, 2012
Webcast link for Q2 and H1 2012 results
June 01, 2012